Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject	STATEMENT OF	CH
to Section 16. Form 4 or Form 5		
obligations may continue. See		

ANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BENEVICH ERIC						2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC NBIX									ionship of Reportir all applicable) Director Officer (give title		10% Ow Other (s		ner
(Last) (First) (Middle) 12780 EL CAMINO REAL						3. Date of Earliest Transaction (Month/Day/Year) 04/15/2020								X	belov Ch	v) nief Comm	iercia	below) al Officer	
(Street) SAN DIEGO CA 92130					4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					on
(City)	(St	ate) (Z	Zip)		Person														
		Table	I - N	lon-Deriva	tive \$	Secui	rities	Ac	quir	ed, Di	sposed c	f, or l	3enefic	ially	Own	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			2A. Deemed Execution Da if any (Month/Day/Y		n Date, Tr		3. Transaction Code (Instr. 8) 4. Securities Ad Disposed Of (D				nd 5) Secur Benet		icially d Following	Forr (D) (wnership m: Direct or rect (I) tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								ď	Code	v	Amount	(A) or (D)	Price	Tran		saction(s) c. 3 and 4)		u. 4)	(111341. 4)
Common	Stock			04/15/202	.0				S ⁽¹⁾		8,632	32 D \$94.6499 ⁽²⁾ 11,603 ⁽³⁾ I		D					
		Tal	ble II	l - Derivati (e.g., pu							posed of, converti				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security			(Instr.	5. Number of Expiration (Month/D Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			iration [Securities Underlying Derivative Security (Ins 3 and 4) Amou or Numb Expiration		unt of rities erlying reative rity (Instr. i 4) Amount or Number of	unt ber		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

- 1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- 2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$92.80 to \$95.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 3. Includes 148 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020.

Remarks:

/s/ Darin Lippoldt, Attorney-

04/17/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.